Esaxerenone
Esaxerenone ( ; brand name Minnebro; developmental codesCS-3150 and XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company.
≈ 1 min read
Esaxerenone. encyclopegia.org, snapshot enwiki-001364601667. /a/esaxerenone
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Esaxerenone ( ; brand name Minnebro; developmental codesCS-3150 and XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company. It is approved in Japan for the treatment of hypertension.
It acts as a highly selective silent antagonist of the mineralocorticoid receptor (MR), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the MR relative to the existing antimineralocorticoids spironolactone and eplerenone. Daiichi Sankyo Company on January 8, 2019 announced the receipt of marketing approval in Japan for Minnebro tablets (1.25 mg, 2.5 mg, and 5 mg) for the treatment of hypertension.
As of January 2019, esaxerenone is in phase III clinical trials for diabetic nephropathies.
See also
Apararenone Finerenone
External links
Esaxerenone - AdisInsight
Text derived from https://en.wikipedia.org/w/index.php?oldid=1364601667 under CC BY-SA 4.0; modifications have been made.